Market Trends Buy this biopharmaceutical stock that can rally 25%, says RBC Capital MarketsBy admin8996erT0allFebruary 25, 2025 Insmed’s bronchiectasis treatment in development offers an opportunity for investors, according to RBC Capital Markets. Analyst Leonid Timashev initiated coverage…
